Form 4: Fulgent Genetics COO Sells Shares for Tax Obligations

Fulgent Genetics' President and COO, Jian Xie, disposed of 4,711 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

Summary

• Jian Xie, President and COO of Fulgent Genetics, Inc. (FLGT), disposed of 4,711 shares of common stock on January 26, 2026.
• The shares were sold at a price of $27.53 per share.
• This disposition was made to satisfy tax withholding obligations that arose upon the vesting of certain restricted stock units.
• These restricted stock units were assumed pursuant to the Agreement and Plan of Merger dated November 7, 2022.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following this transaction, Mr. Xie directly beneficially owns 332,038 shares of common stock.
• Mr. Xie indirectly beneficially owns 220,816 shares through The Hsieh Family Dynasty Trust, dated January 27, 2010, where he serves on the investment committee.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax purposes, which is neither inherently positive nor negative for the company's operational or financial outlook. It is a standard event for executives receiving equity compensation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports a routine insider transaction for tax purposes, which is specific to the individual executive and does not reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine tax-related sale and does not indicate a change in the executive's confidence in the company or its fundamentals.

Key Dates

Recommendation

The Form 4 details a routine insider sale of shares to cover tax obligations upon RSU vesting, executed under a pre-arranged 10b5-1 plan. This type of transaction is common and does not typically reflect a change in management's confidence or the company's fundamental performance, thus not warranting a change in investment recommendation based solely on this filing.

Keywords

Fulgent Genetics, FLGT, insider transaction, Form 4, stock sale, executive compensation, restricted stock units, tax withholding, 10b5-1 plan